Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?

References

• Chiappini E, Venturini E, Bonsignori F, Galli L, de Martino M. Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaign. Acta Paediatr 2010:1609-1614; PMID:20545931; http://dx.doi.org/10.1111/j.1651-2227.2010.01908.x
   PubMedGoogle Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20:S58-67; PMID:11587814; http://dx.doi.org/10.1016/S0264-410X(01)00299-7
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326:365-366; PMID:12586669; http://dx.doi.org/10.1136/bmj.326.7385.365
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-743; PMID:18271745; http://dx.doi.org/10.1086/527401
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Miller E, Clark S, Sadler F, Fox A, Begg N, Morris R, Cartwright K. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999; 179:1569-1572; PMID:10228085; http://dx.doi.org/10.1086/314753
   PubMed Web of Science ®Google Scholar
• Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840-847; PMID:20219881; http://dx.doi.org/10.1128/CVI.00529-09
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780-786; PMID:12965904
   PubMedGoogle Scholar
• Borrow R1, Goldblatt D, Andrews N, Southern J, Ashton L, Deane S, Morris R, Cartwright K, Miller E. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. J Infect Dis 2002; 186:1353-1357; PMID:12402208; http://dx.doi.org/10.1086/344324
   PubMed Web of Science ®Google Scholar
• Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, Miller E. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006; 194:1745-1752; PMID:17109348; http://dx.doi.org/10.1086/509619
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Findlow H, Waight P, Southern J, Crowley-Luke A, Stapley L, England A, Findlow J, Miller E. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccin Immunol 2010; 17:154-159; PMID:19906895; http://dx.doi.org/10.1128/CVI.00384-09
   PubMed Web of Science ®Google Scholar
• Trotter CL1, Borrow R, Findlow J, Holland A, Frankland S, Andrews NJ, Miller E. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. See comment in PubMed Commons below. Clin Vaccine Immunol 2008; 15:1694-8; PMID:18827191; http://dx.doi.org/10.1128/CVI.00279-08
   PubMed Web of Science ®Google Scholar
• Ishola DA Jr, Borrow R, Findlow H, Findlow J, Trotter C, Ramsay ME. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol 2012; 19:1126-1130; PMID:22647271; http://dx.doi.org/10.1128/CVI.05655-11
   PubMed Web of Science ®Google Scholar
• Southern J, Borrow R, Andrews N, Morris R, Waight P, Hudson M, Balmer P, Findlow H, Findlow J, Miller E. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol 2009; 16:194-199; PMID:19091990; http://dx.doi.org/10.1128/CVI.00420-08
   PubMed Web of Science ®Google Scholar
• Findlow H, Borrow R, Andrews N, Waight P, Sheasby E, Matheson M, England A, Goldblatt D, Ashton L, Findlow J, et al. Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United Kingdom. Pediatr Infect Dis J 2012; 31:616-622; PMID:22333698; http://dx.doi.org/10.1097/INF.0b013e31824f34e6
   PubMed Web of Science ®Google Scholar
• Poellabauer EM, Pavlova BG, Fritsch S, Singer J, Neubauer C, Doralt J, Valenta-Singer B, Ehrlich HJ. Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C®) in infants. Vaccine 2013; 31:3611-3616; PMID:23672977; http://dx.doi.org/10.1016/j.vaccine.2013.04.070
   PubMedGoogle Scholar
• Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, Andrews N, Lal G, Riley C, Rahim R, Cartwright K, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect Immun 2003; 71:5549-5555; PMID:14500473; http://dx.doi.org/10.1128/IAI.71.10.5549-5555.2003
   PubMed Web of Science ®Google Scholar
• Díez-Domingo J1, Cantarino MV, Torrentí JM, Sansano MI, Rosich AJ, Merino AH, de Miguel AG, González JB, Marcos MD; MenC Study Group. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J 2010; 29:148-152; PMID:19927040; http://dx.doi.org/10.1097/INF.0b013e3181b9a831
   PubMed Web of Science ®Google Scholar
• Pace D, Khatami A, McKenna J, Campbell D, Attard-Montalto S, Tajar A, Birks J, White C, Finn A, Macloed E, et al. Immunogenicity of a reduced conjugate Meningococcal Serogorup C vaccination schedule in infancy. European Society of Pediatric Infectious Diseases, Milan, Italy; 2013.
   Google Scholar
• Khatami A, Clutterbuck EA, Thompson AJ, McKenna JA, Pace D, Birks J, Snape MD, Pollard AJ. Evaluation of the induction of immune memory following infant immunisation with aerogroup C Neisseria meningitidis conjugate vaccines - exploratory analyses within a randomised controlled trial. PLoS One 2014; 9:e101672; EPUB; PMID:25020050; http://dx.doi.org/10.1371/journal.pone.0101672
   PubMedGoogle Scholar
• Ladhani S, Andrews N, Waight P, Hallis B, Matheson M, England A, Findlow H, Bai X, Borrow R, Goldblatt D, et al. Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule. Vaccine 2015; 33:648-55.
   Google Scholar
• Department of Health/Public Health England. Changes to the schedule for meningococcal serogroup C conjugate vaccine 7 May 2013.
   Google Scholar
• de Whalley PC1, Snape MD, Plested E, Thompson B, Nuthall E, Omar O, Borrow R, Pollard AJ. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Arch Dis Child 2013; 98:686-691; PMID:23853000; http://dx.doi.org/10.1136/archdischild-2013-303893
   PubMed Web of Science ®Google Scholar
• EMEA:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002333/human_med_001614.jsp& Accessed 18/07/2014
   Google Scholar
• JCVI. JCVI position statement on use of Bexsero® meningococcal B vaccine in the UK. 21st March 2014
   Google Scholar